CN1255041A - 治疗与爱滋病相关的卡波西肉瘤的方法和成分 - Google Patents

治疗与爱滋病相关的卡波西肉瘤的方法和成分 Download PDF

Info

Publication number
CN1255041A
CN1255041A CN98805000A CN98805000A CN1255041A CN 1255041 A CN1255041 A CN 1255041A CN 98805000 A CN98805000 A CN 98805000A CN 98805000 A CN98805000 A CN 98805000A CN 1255041 A CN1255041 A CN 1255041A
Authority
CN
China
Prior art keywords
treatment
patient
taxol
aids
kaposi sarcoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98805000A
Other languages
English (en)
Chinese (zh)
Inventor
K·L·密特廷格
K·都彻恩
S·格里芬
G·R·哈里曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharmaceuticals Inc filed Critical Baker Cummins Pharmaceuticals Inc
Publication of CN1255041A publication Critical patent/CN1255041A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
CN98805000A 1998-03-30 1998-03-30 治疗与爱滋病相关的卡波西肉瘤的方法和成分 Pending CN1255041A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/006221 WO1999065307A1 (en) 1998-03-30 1998-03-30 Methods and compositions for treatment of aids-associated kaposi's sarcoma

Publications (1)

Publication Number Publication Date
CN1255041A true CN1255041A (zh) 2000-05-31

Family

ID=22266711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98805000A Pending CN1255041A (zh) 1998-03-30 1998-03-30 治疗与爱滋病相关的卡波西肉瘤的方法和成分

Country Status (6)

Country Link
EP (1) EP1071329A4 (ja)
JP (1) JP2002518297A (ja)
CN (1) CN1255041A (ja)
AU (1) AU6787398A (ja)
CA (1) CA2301665A1 (ja)
WO (1) WO1999065307A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents

Also Published As

Publication number Publication date
AU6787398A (en) 2000-01-05
JP2002518297A (ja) 2002-06-25
EP1071329A4 (en) 2001-05-02
WO1999065307A1 (en) 1999-12-23
EP1071329A1 (en) 2001-01-31
CA2301665A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
Noppers et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases
RU2576609C2 (ru) Способы лечение рака поджелудочной железы
JP2013518124A5 (ja)
Woo et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma
WO2020146770A1 (en) Methods for the prevention or treatment of cytokine storm, and for preventing diseases or conditions caused by cytokine storm
Nakao et al. Possibility of Müller cell dysfunction as the pathogenesis of paclitaxel maculopathy
Gore et al. Funding the elimination of viral hepatitis: donors needed
RU2371195C2 (ru) Способ лечения вирусных инфекций
Shingina et al. In a ‘real‐world’, clinic‐based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival
Hayes et al. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors
TWI797426B (zh) 西奧羅尼用於小細胞肺癌的治療
CN1255041A (zh) 治疗与爱滋病相关的卡波西肉瘤的方法和成分
CN115177620A (zh) 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
Koschmieder et al. Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: pre-specified interim analysis of the randomized phase 2b Ruxobeat clinical trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Li et al. Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial
CN115397431A (zh) 用于治疗涉及全身过度炎症反应的病症的eclitasertib
Mostafavi et al. Successful recovery of a child with COVID-19-induced secondary hemophagocytic lymphohistiocytosis
Tho et al. Guillain–Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer
Saag et al. Case 36-2019: A 34-Year-Old Man with Dyspnea, Odynophagia, and Abdominal Pain
CN106466306A (zh) 含维甲酸和索拉非尼的药物组合物及其应用
CN104138386A (zh) 柴胡皂苷d对肿瘤多药耐药逆转作用的医药用途
Aguirre et al. Severe thrombocytopenia related to long-term trastuzumab exposure
WO2017114215A1 (zh) 重组人钙调磷酸酶b亚基的应用
Anghelescu et al. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior
Sands et al. A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1026343

Country of ref document: HK